Displaying 81 - 100 of 590
Commission Order Vacates ALJ Initial Decision and Dismisses Complaint in Case Against Altria and Juul
Date
On Friday, June 30, 2023, the Federal Trade Commission vacated the Administrative Law Judge’s (ALJ) initial decision in the administrative litigation challenging an alleged unlawful agreement between...
Applied Medical Resources Corp. v. Medtronic, Inc.
Date
Citation Number
8:23-cv-00268
Federal Court
Central District of California
File
FTC Files Amicus Brief to Clarify Antitrust Standards Involving Exclusive-Dealing and Bundling Arrangements
Date
The Federal Trade Commission filed a friend-of-the-court (amicus) brief in the U.S. District Court for the Central District of California, clarifying legal standards that apply in antitrust cases...
In Re Bystolic Antitrust Litigation
Date
Citation Number
23-410
Federal Court
U.S. Circuit Court of Appeals for the Second Circuit
The Commission urges the Second Circuit to reverse the district court’s decision dismissing the private plaintiffs’ reverse-payment complaints for failure to state a claim and clarifies the...
File
Brief of Amicus Curiae
(443.34 KB)
FTC Files Amicus Brief in Bystolic Antitrust Litigation Supporting Competition in the Hypertension Drug Market
Date
The Federal Trade Commission filed a friend-of-the-court (amicus) brief in the U.S. Court of Appeals for the Second Circuit, clarifying the legal standards that apply in certain antitrust cases...
FTC Further Expands Inquiry Into Prescription Drug Middlemen Industry Practices
Date
As part of its ongoing study on pharmacy benefit managers (PBMs) and their impact on the accessibility and affordability of prescription drugs, the Federal Trade Commission has issued a compulsory...
FTC Approves Final Order Requiring Anchor Glass Container Corp. to Drop Noncompete Restrictions That It Imposed on Workers
Date
Following a public comment period, the Federal Trade Commission finalized a consent order settling charges that Anchor Glass Container Corp. illegally imposed noncompete restrictions on more than 300...
FTC Approves Publication of Federal Register Notice on Revisions to Parts 0-4 of the Commission’s Rules of Practice
Date
The Federal Trade Commission voted to modify several sections of the agency’s Rules of Practice to reflect the creation of the FTC’s Office of Technology, revise the Commission’s administrative...
Anchor Glass
Type of Action
Administrative
Last Updated
FTC Matter/File Number
2110182
Docket Number
C-4793
Case Status
Pending
FTC Deepens Inquiry into Prescription Drug Middlemen
Date
As part of its ongoing inquiry into pharmacy benefit managers (PBMs) and their impact on the accessibility and affordability of prescription drugs, the Federal Trade Commission has issued compulsory...
FTC, Justice Department, and European Commission Hold Third U.S.- EU Joint Technology Competition Policy Dialogue
Date
Federal Trade Commission Chair Lina M. Khan, the Justice Department’s Antitrust Division Assistant Attorney General Jonathan Kanter, and Executive Vice President Margrethe Vestager of the European...
FTC and Justice Department to Hold Annual Spring Enforcers Summit
Date
The Federal Trade Commission and the Justice Department’s Antitrust Division will cohost the second Spring Enforcers Summit on Monday, March 27th. Federal Trade Commission Chair Lina M. Khan and...
FTC Takes Action Against Another Company That Imposed Harmful Noncompete Restrictions on Its Workers
Date
The Federal Trade Commission ordered manufacturing company Anchor Glass Container Corp. to drop noncompete restrictions that it imposed on its workers, the fourth time this year that the agency has...
Endo Pharmaceuticals Inc./Amneal Pharmaceuticals, Inc.
The FTC is suing Endo Pharmaceuticals, Inc., Endo International plc, Impax Laboratories, LLC, and Impax’s owner, Amneal Pharmaceuticals, Inc., alleging that a 2017 agreement between Endo and Impax violated the antitrust laws by eliminating competition in the market for oxymorphone ER. The complaint charges the defendants with violating Sections 1 and 2 of the Sherman Act, which constitutes unfair methods of competition in violation of Section 5 of the FTC Act. Specifically, Endo, Impax, and Amneal are charged with entering into an illegal agreement in restraint of trade, and Amneal is charged with monopolization of the oxymorphone ER market. The complaint was filed in the U.S. District Court for the District of Columbia on Jan. 25, 2021.
Type of Action
Federal
Last Updated
FTC Matter/File Number
1910104
Prudential Security, et al., In the Matter of
Type of Action
Administrative
Last Updated
FTC Matter/File Number
2210026
Case Status
Pending
FTC Approves Final Orders Requiring Two Glass Container Manufacturers to Drop Noncompete Restrictions That They Imposed on Workers
Date
Following a public comment period, the Federal Trade Commission finalized consent orders settling charges that two glass container manufacturers, O-I Glass, Inc. and Ardagh Group S.A. illegally...
Displaying 81 - 100 of 590